/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

NovaBay Pharmaceuticals Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$1.06 0.0392(3.92%) NBY at 04 Dec 2025 04:39 PM Biotechnology
Lowest Today 1.01
Highest Today 1.06
Today’s Open 1.01
Prev. Close 1.02
52 Week High 2.93
52 Week Low 0.30
Day’s Range: Low 1.01 High 1.06
52-Week Range: Low 0.30 High 2.93
1 day return -
1 Week return +2.94
1 month return -6.25
3 month return -74.94
6 month return +77.18
1 year return +77.96
3 year return -98.47
5 year return -99.86
10 year return -

Institutional Holdings

Market Status

Strong Buy: 1

Buy: 0

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 128.53 M

PB Ratio 2.1677

PE Ratio 0.2112

Enterprise Value 139.80 M

Total Assets 3.42 M

Volume 43725

Company Financials

Annual Revenue FY23:14642000 14.6M, FY22:14404000 14.4M, FY21:8421000 8.4M, FY20:9934000 9.9M, FY19:6599000 6.6M

Annual Profit FY23:7835000 7.8M, FY22:7781000 7.8M, FY21:5645000 5.6M, FY20:5964000 6.0M, FY19:4861000 4.9M

Annual Net worth FY23:-13738000 -13.7M, FY22:-16265000 -16.3M, FY21:-6559000 -6.6M, FY20:-11039000 -11.0M, FY19:-10487000 -10.5M

Quarterly Revenue Q3/2025:521000 0.5M, Q2/2025:0 0.0M, Q1/2025:2309000 2.3M, Q3/2024:2441000 2.4M, Q2/2024:2400000 2.4M

Quarterly Profit Q3/2025:42000 0.0M, Q2/2025:-38000 -0.0M, Q1/2025:1502000 1.5M, Q3/2024:1593000 1.6M, Q2/2024:1592000 1.6M

Quarterly Net worth Q3/2025:-1293000 -1.3M, Q2/2025:-1922000 -1.9M, Q1/2025:7670000 7.7M, Q3/2024:-1212000 -1.2M, Q2/2024:-1585000 -1.6M

Fund house & investment objective

Company Information NovaBay Pharmaceuticals, Inc. does not have significant operations. Previously, the company was engaged in the development and sale of eyecare, wound care, and skin care products in the United States and internationally. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.

Organisation Biotechnology

Employees 13

Industry Biotechnology

CEO Michael Kazley

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow